All In Biotech

Drug Trial Radar · NCT05689047

Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Mar 29, 2023

Primary completion

May 28, 2024

Study completion May 28, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety, efficacy, and pharmacokinetic of the combination M5717 plus pyronaridine in participants with acute uncomplicated Plasmodium falciparum malaria.

Conditions

  • Acute Malaria

Interventions

  • M5717 330 mgDrug

    Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.

  • M5717 500 mgDrug

    Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.

  • M5717 660 mgDrug

    Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.

  • Pyronaridine 360 mgDrug

    Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.

  • Pyronaridine 360 mgDrug

    Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.

  • Pyronaridine 540 mgDrug

    Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.

  • Pyronaridine 720 mgDrug

    Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEsTime frame: Day 1 up to Day 43
  2. Cohort A: Number of Participants With Clinically Significant Change From Baseline in Safety Laboratory ParametersTime frame: Day 1 up to Day 29
  3. Cohort A: Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiogram (ECG) FindingsTime frame: Day 1 up to Day 29
  4. Cohort A: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Day 1 up to Day 29
  5. Cohort B0: Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR)Time frame: At Day 29

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • Institut de Recherche en Sciences de la Santé (IRSS)

    Nanoro, Burkina Faso

  • Groupe de Recherche Action en Santé (GRAS)

    Ouagadougou, Burkina Faso

  • Centre de Recherches Médicales de Lambaréné (CERMEL)

    Lambaréné, Gabon

  • Centro de Investigação em saúde de Manhiça/Fundação Manhiça (CISM/FM)

    Maputo, Mozambique

  • Infectious Diseases Research Collaboration (IDRC)

    Tororo, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.